Related Experiment Video
Updated: Jul 16, 2026

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α
Published on: November 2, 2018
Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B
F G Wulczyn1, M Naumann, C Scheidereit
1Otto Warburg Laboratorium, Max Planck Institut für Molekulare Genetik, Berlin, Germany.
Abstract:
The NF-kappa B subunits p50 and p65 and the product of the rel proto-oncogene are members of a growing class of transcription factors with a unique DNA-binding and dimerization domain. Nuclear transfer of each of these factors is controlled by cytoplasmic inhibitors, and regulated by specific stimuli. The inhibitors I kappa B-alpha and -beta and pp40 recognize either p65 or the c-rel protein. We show here that the proto-oncogene bcl-3, believed to be involved in certain human B-cell leukaemias, encodes a protein that functions as an I kappa B-like molecule for native NF-kappa B but is specific for the p50 subunit. The ankyrin repeat domain of the bcl-3 product is shown to mediate complex formation with NF-kappa B dimers by contracting the conserved dimerization domain of NF-kappa B.
Insights
The proto-oncogene bcl-3 encodes a protein that acts as a specific inhibitor for the NF-kappa B p50 subunit. This finding reveals a new regulatory mechanism for NF-kappa B transcription factors involved in cell growth and disease.
Area of Science:
- Molecular Biology
- Cellular Biology
- Oncogenesis
Background:
- Nuclear factor kappa B (NF-kappa B) and related proteins (p50, p65, c-rel) are transcription factors with unique DNA-binding and dimerization domains.
- Their nuclear translocation is regulated by cytoplasmic inhibitors, including I kappa B-alpha, I kappa B-beta, and pp40, which target p65 or c-rel.
- The proto-oncogene bcl-3 is implicated in human B-cell leukaemias.
Purpose of the Study:
- To investigate the function of the bcl-3 proto-oncogene product in relation to NF-kappa B transcription factors.
- To determine if bcl-3 acts as a cytoplasmic inhibitor for NF-kappa B subunits.
- To elucidate the mechanism by which bcl-3 interacts with NF-kappa B.
Main Methods:
- Analysis of the bcl-3 gene product's function.
- Investigation of protein-protein interactions between bcl-3 and NF-kappa B subunits.
- Characterization of the role of the ankyrin repeat domain in bcl-3.
Main Results:
- The bcl-3 product functions as an I kappa B-like molecule.
- bcl-3 specifically inhibits the NF-kappa B p50 subunit, unlike other known inhibitors.
- The ankyrin repeat domain of bcl-3 mediates complex formation with NF-kappa B dimers by contracting the dimerization domain.
Conclusions:
- The bcl-3 proto-oncogene encodes a novel I kappa B-like inhibitor specific for the NF-kappa B p50 subunit.
- This interaction regulates NF-kappa B activity and has implications for understanding human B-cell leukaemias.
- bcl-3 represents a new target for studying NF-kappa B pathway regulation.
More Related Videos
Related Concept Videos
Co-activators and Co-repressors
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

